Complete inhibition of viral breakthrough by combination of MKC-442 with AZT during a long-term culture of HIV-1-infected cells

Antiviral Research

Volumn 31, Issue 1-2, 1996, Pages 69-77

  Okamoto, Mika ^a   Makino, Masahiko ^a   Yamada, Kazunori ^b   Nakade, Kouji ^b   Yuasa, Satoshi ^b   Baba, Masanori ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b MITSUBISHI CHEMICAL CORPORATION   (Japan)

Author keywords

Combination chemotherapy; Drug resistance; HEPT derivative; HIV 1; Non nucleoside reverse transcriptase inhibitor (NNRTI)

Indexed keywords

EMIVIRINE; LOVIRIDE; NEVIRAPINE; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESISTANCE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; PRIORITY JOURNAL; VIRUS INHIBITION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029944278     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(96)00946-1     Document Type: Article

References (24)

1. Baba, M., Tanaka, H., De Clercq, E., Pauwels, R., Balzarini, J., Schols, D., Nakashima, H., Perno, C.-F., Walker, R.T. and Miyasaka T., (1989) Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 165, 1375-1381.
2. Baba, M., De Clercq, E., Tanaka, H., Ubasawa, M., Takashima, H., Sekiya, K., Nitta, I., Umezu, K., Nakashima, H., Mori, S., Shigeta, S., Walker, R.T. and Miyasaka, T., (1991a) Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 88, 2356-2360.
3. Baba, M., De Clercq, E., Tanaka, H., Ubasawa, M., Takashima, H., Sekiya, K., Nitta, I., Umezu, K., Walker, R.T., Mori, S., Ito, M., Shigeta, S. and Miyasaka, T., (1991b) Highly potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by a novel series of 6-substituted acyclouridine derivatives. Mol. Pharmacol. 39, 1430-1433.
4. Baba, M., Shigeta, S., Yuasa, S., Takashima, H., Sekiya, K., Ubasawa, M., Tanaka, H., Miyasaka, T., Walker, R.T. and De Clercq, E. (1994) Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38, 688-692.
5. Baba, M., Tanaka, H., Miyasaka, T., Yuasa, S., Ubasawa, M., Walker, R.T. and De Clercq, E. (1995) HEPT derivatives: 6-Benzyl-1-ethoxymethyl-5-isopropyluracil (MKC-442). Nucleosides Nucleotides 14, 575-583.
6. Balzarini, J., Karlsson, A., Pèrez-Pèrez, M.-J., Camarasa, M.-J., and De Clercq, E., (1993a) Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196, 576-585.
7. Balzarini, J., Karlsson, A., Vandamme, Pèrez-Pèrez, M.-J., Vrang, L., Walbers, J., Zhang, H., Öberg, B., Vandamme, A.-M., Camarasa, M.-J., and De Clercq, E., (1993b) HIV-1 specific reverse transcriptase inhibitors show differential activity against HIV-1 mutant strains containing different amino acid substitutions in the reverse transcriptase. Virology 192, 246-253.
8. Balzarini, J., Baba, M. and De Clercq, E. (1995) Differential activities of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)-thymine derivatives against different human immunodeficiency virus type 1 mutant strains. Antimicrob. Agents Chemother. 39, 998-1002.
9. Byrnes, V.W., Sardana, V.V., Schleif, W.A., Condra, J.H., Waterbury, J.A., Wolfgang, J.A., Long, W.J., Schneider, C.L., Schlabach, A.J., Wolanski, B.S., Graham, D.J., Gotlib, L., Rhodes, A., Titus, D.L., Roth, E., Blahy, O.M., Quintero, J.C., Staszewski, S. and Emini, E.A. (1993) Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to non-nucleoside inhibitors. Antimicrob. Agents Chemother. 37, 1576-1579.
10. Chow, Y.-K., Hirsch, M.S., Merrill, D.P., Bechtel, L.J., Eron, J.J., Kaplan, J.C. and D'Aquila, R.T. (1993) Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy. Nature 361, 650-654.
11. De Clercq, E. (1994) HIV resistance to reverse transcriptase inhibitors. Biochem. Pharmacol. 47, 155-169.
12. Goldman, M.E., Nunberg, J.H., O'Brien, J.A., Quintero, J.C., Schleif, W.A., Freund, K.F., Gaul, S.L., Saari, W.S., Wai, J.S., Hoffman, J.M., Anderson, P.S., Hupe, D.J., Emini, E.A. and Stern, A.M. (1991) Pyridinon derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity. Proc. Natl. Acad. Sci. USA 88, 6863-6867.
13. Merluzzi, V.J., Margrave, K.D., Labadia, M., Grozinger, K., Skoog, M., Wu, J.C., Shih, C.-K., Eckner, K., Hattox, S., Adams, J., Rosenthal, A.S., Faanes, R., Eckner, R.J., Koup, R.A. and Sullivan, J.L. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250, 1411-1413.
14. Miyasaka, T., Tanaka, H., Baba, M., Hayakawa, H., Walker, R.T., Balzarini, J. and De Clercq, E. (1989) A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J. Med. Chem. 32, 2507-2509.
15. Miyoshi, I., Taguchi, H., Kubonishi, I., Yoshimoto, S., Ohtsuki, Y., Shiraishi, Y. and Akagi, T. (1982) Type C virus producing cell lines derived from adult T cell leukemia. Gann Monogr. 28, 219-228.
16. Ou, C.-Y., Kwok, S., Mitchell, S.W., Mack, D.H., Sninsky, J.J., Krebs, J.W., Feorino, P., Warfield, D. and Schochetman, G. (1988) DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 239, 295-297.
17. Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdewijn, P., Desmyter, J. and De Clercq, E. (1988) Rapid and automated tetrazolium-based calorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20, 309-321.
18. Pauwels, R., Andries, K., Desmyter, J., Schols, D., Kukla, M.J., Breslin, A., Raeymaeckers, J., Van Gelder, J., Woestenborghs, R., Heykants, J., Schellekens, K., Janssen, M.A.C., De Clercq, E. and Janssen, P.A.J. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343, 470-474.
19. Pauwels, R., Andries, K., Debyser, Z., Daele, P.V., Schols, D., Stoffels, P., Vreese, K.D., Woestenborghs, R., Vandamme, A.-M., Janssen, C.G.M., Anne, J., Cauwenbergh, G., Desmyter, J., Heykants, J., Janssen, M.A.C., De Clercq, E. and Janssen, P.A.J. (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of α-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 90, 1711-1715.
20. Ratner, L., Haseltine, W., Patarca, R., Livak, K.J., Starcich, B., Josephs, S.T., Doran, E.R., Rafalski, J.A., Whitehorn, E.A., Baumeiser, K., Ivanoff, L., Petteway Jr., S.R., Pearson, M.L., Lautenberger, J.A., Papas, T.S., Ghrayeb, J., Cheng, N.T., Gallo, R.C. and Wong-Staal, F. (1985) Complete nucleotide sequence of the AIDS virus, HTLV-3. Nature 313, 277-284.
21. Richman, D.D., Havlir, D., Corbeil, J., Looney, D., Ignacio, C., Spector, S.T., Sullivan, J., Cheeseman, S., Barringer, K., Pauletti, D., Shih, C.-K., Myers, M. and Griffin, J. (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68, 1660-1666.
22. Seki, M., Sadakata, Y., Yuasa, S. and Baba, M. (1995) Isolation and characterization of human immunodeficiency virus type 1-mutants resistant to the non-nucleotide reverse transcriptase inhibitor MKC-442. Antiviral Chem. Chemother. 6, 73-79.
23. Tanaka, H., Takashima, H., Ubasawa, M., Sekiya, K., Inoue, N., Baba, M., Shigeta, S., Walker, R.T., De Clercq, E. and Miyasaka, T. (1995) Synthesis and antiviral activity of 6-benzyl analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J. Med. Chem. 38, 2860-2865.
24. Yuasa, S., Sadakata, Y., Takashima, H., Sekiya, K., Inoue, N., Ubasawa, M and Baba, M. (1993) Selective and synergistic inhibition of human immunodeficiency virus type 1 reverse transcriptase by a non-nucleoside inhibitor, MKC-442. Mol. Pharmacol. 44, 895-900.